ZYNE Zynerba Pharmaceuticals EPS misses by $0.01 Nov. 15, 2021 7:24 AM ETZynerba Pharmaceuticals, Inc. (ZYNE)By: Meghavi Singh, SA News Editor Zynerba Pharmaceuticals (NASDAQ:ZYNE): Q3 GAAP EPS of -$0.26 misses by $0.01. As of September 30, 2021, cash and cash equivalents were $75.6M, compared to $59.2M as of December 31, 2020. Management believes that the Company’s cash and cash equivalents as of September 30, 2021 are sufficient to fund operations and capital requirements well into the first half of 2024. Press Release Read: Palisade Bio reports Q3 results Save Share Comment Recommended For You Comments Newest Have a tip? Submit confidentially to our News team. Found a factual error? Report here. More Trending News

PBI дивы https://finance.yahoo.com/news/pitney-bowes-declares-common-stock-151000218.html

PBI вроде выиграли гос контракт